The oversubscribed round included backing from Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence.
"This substantial investment round demonstrates continued confidence in the progress of our technical development and its potential to revolutionise the accessibility of gene synthesis. Evonetix is in a very exciting phase, having recently opened our early access program. This investment will support us as we execute on our commercial strategy to put benchtop gene synthesis in the hands of users."
The oversubscribed round drew backing from Remus Capital, Plug and Play, and Innovate UK alongside notable angel investors.
"We are very excited by the research and commercial potential of the Syndi Health platform. It will help us understand how better to support the mental health needs of our people and offer them the personalised digital support they need at the earliest opportunity, which is invaluable."
The funding was awarded by the Center for Connected Autonomous Vehicles to back the Hub2Hub hydrogen vehicle project.
"Our market analysis indicates that the commercial vehicle segments such as haulage are where we will see autonomous vehicle technology first used in large scale deployments. Hub2Hub is a perfect showcase of what the advanced version of our CAVstar Automated Drive System can achieve. Combining SAE Level 4 autonomous driving with tele-operation to deliver safer and more efficient vehicle operations."
